Selected article for: "active compound and antiviral activity"
Author: Ross D. Overacker; Somdev Banerjee; George F. Neuhaus; Selena Milicevic Sephton; Alexander Herrmann; James A. Strother; Ruth Brack-Werner; Paul R. Blakemore; Sandra Loesgen
Title: Biological Evaluation of Molecules of the azaBINOL Class as Antiviral Agents: Specific Inhibition of HIV-1 RNase H Activity by 7-Isopropoxy-8-(naphth-1-yl)quinoline
  • Document date: 2019_1_23
    • ID: m2zw8eq4_14
    Snippet: The single round infectivity assay using HIV-1 enveloped pseudotyped viruses is able to 195 report on inhibition of early stages of infection including cell entry, reverse transcription, and 196 integration steps. The active azaBINOL compound B#24 inhibited all HIV-1 strains tested 197 regardless of their differing viral tropism (HXB2, YU2, and 89.6). This broad inhibition 198 indicated that the antiviral mode-of-action is unlikely to rely on the.....
    Document: The single round infectivity assay using HIV-1 enveloped pseudotyped viruses is able to 195 report on inhibition of early stages of infection including cell entry, reverse transcription, and 196 integration steps. The active azaBINOL compound B#24 inhibited all HIV-1 strains tested 197 regardless of their differing viral tropism (HXB2, YU2, and 89.6). This broad inhibition 198 indicated that the antiviral mode-of-action is unlikely to rely on the viral fusion process, as 199 changing the surface glycoprotein does not affect antiviral activity. Additionally, the EASY-HIT temsavir, which loses activity if dosed post viral entry. Instead, B#24 remains active throughout 207 the assay, but exhibits a subtle decrease in antiviral activity between 6-8 hours post infection. 208

    Search related documents:
    Co phrase search for related documents
    • action antiviral mode and antiviral mode: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • action antiviral mode and cell entry: 1
    • action antiviral mode and early stage: 1
    • action antiviral mode and post infection: 1
    • active azaBINOL compound and antiviral activity: 1
    • active azaBINOL compound and azaBINOL compound: 1
    • active remain and cell entry: 1
    • activity lose and antiviral activity: 1
    • activity lose and post infection: 1
    • antiviral activity and azaBINOL compound: 1, 2
    • antiviral activity and broad inhibition: 1, 2, 3, 4, 5
    • antiviral activity and cell entry: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • antiviral activity and early stage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • antiviral activity and fusion process: 1, 2, 3, 4, 5, 6, 7, 8
    • antiviral activity and hour post infection: 1
    • antiviral activity and infectivity assay: 1, 2, 3, 4, 5
    • antiviral activity and post infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • antiviral mode and cell entry: 1
    • antiviral mode and early stage: 1